- Emmanuel PETIOT will resign as Chief Executive Officer ("CEO") as of December 31, 2019
- Dr. Charles WOLER, Chairman of the Board of Directors, will act as interim CEO pending the appointment of a new CEO
- Emmanuel PETIOT has been appointed director of DEINOVE with a focus on supporting the Company’s partnerships
DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company that uses a disruptive approach to develop innovative antibiotics and bio-based active ingredients for cosmetics and nutrition, announces that the Board of Directors of the Company has acknowledged Emmanuel Petiot's decision to resign as CEO of DEINOVE and has decided, in consultation with Emmanuel Petiot, that his duties will end on 31 December 2019.
Dr. Charles Woler, currently Chairman of the Board of Directors of DEINOVE, has been appointed interim CEO as of 1st January 2020. The Board of Directors has already begun the process of recruiting a new CEO to pursue the Company's high-potential activities’ development, and in particular the upgrading of its research and development services.
In order to facilitate the transition and support its current and future scientific and industrial partnerships, the Company's Board of Directors has co-opted Emmanuel Petiot as a director to replace Bernard Fanget, who has resigned.
"On behalf of the Board of Directors, I would like to express our gratitude to Emmanuel Petiot for his ongoing commitment over these seven years and for the enthusiasm with which he led DEINOVE and led its strategic refocus on antibiotics and high value-added active bioingredients in cosmetics. We are grateful to him and wish him every success in his future career. We have full confidence in the management team he has formed to ensure that this evolution in DEINOVE's governance will not have an impact on ongoing projects and that DEINOVE will continue to further develop" said Dr. Charles Woler.